Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Symbol
- RVMD
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $41.32B
- 52 week range
- 42.18 - 224.31
Valuation
- Share price
- $190.74 (close of 2026-09-23)
- P/E (TTM)
- -21.77x
- Price to book
- 15.85x
- Price to free cash flow
- -33.53x
- Enterprise value
- $41.15B
- Book value per share
- $12.16
Price performance
| Period | Change |
|---|
| 1 day | -1.05% |
| 5 days | -6.89% |
| 1 month | -8.94% |
| 3 months | +12.52% |
| 6 months | +97.39% |
| Year to date | +139.47% |
| 1 year | +331.44% |
| 3 years | +535.80% |
| 5 years | +497.56% |
| All time | +560.00% |
Profitability and growth
- Return on equity
- -69.35%
- Return on invested capital
- -84.08%
- Return on assets
- -48.05%
- Return on capital employed
- -57.28%
- Revenue growth
- 0.00%
- Net income growth
- -88.52%
- Free cash flow growth
- -60.94%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -2.98%
- Current ratio
- 11.38x
- Net debt to EBITDA
- 0.10x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- EBITDA
- $-1.17B
- Net income
- $-1.13B
- Earnings per share
- $-5.95
- Research and development
- $987.33M
- Shares outstanding
- 190.13M
Income statement by year
| Period end | Revenue | Net income | EPS |
|---|
| 2025-12-31 | - | $-1.13B | $-5.95 |
| 2024-12-31 | - | $-600.09M | $-3.58 |
| 2023-12-31 | $11.58M | $-436.37M | $-3.86 |
| 2022-12-31 | $35.38M | $-248.71M | $-3.08 |
| 2021-12-31 | $29.39M | $-187.09M | $-2.57 |
| 2020-12-31 | $42.98M | $-108.16M | $-2.01 |
| 2019-12-31 | $50.04M | $-47.66M | $-22.33 |
| 2018-12-31 | $20.16M | $-41.79M | $-21.24 |
Margins and returns by year
| Period end | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | - | -69.35% | -84.08% |
| 2024-12-31 | - | -26.49% | -37.07% |
| 2023-12-31 | -3768.28% | -23.89% | -39.71% |
| 2022-12-31 | -702.95% | -36.30% | -43.85% |
| 2021-12-31 | -636.58% | -31.05% | -33.53% |
| 2020-12-31 | -251.63% | -22.79% | -27.37% |
| 2019-12-31 | -95.25% | 31.24% | - |
| 2018-12-31 | -207.24% | 38.54% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $383.75M |
| 2024-12-31 | $543.06M |
| 2023-12-31 | $696.15M |
| 2022-12-31 | $161.41M |
| 2021-12-31 | $108.50M |
| 2020-12-31 | $104.27M |
| 2019-12-31 | $16.66M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-913.73M | $118.39M |
| 2024-12-31 | $-567.74M | $79.20M |
| 2023-12-31 | $-358.30M | $61.77M |
| 2022-12-31 | $-235.22M | $31.20M |
| 2021-12-31 | $-153.71M | $20.72M |
| 2020-12-31 | $-103.00M | $8.89M |
| 2019-12-31 | $-52.20M | $3.16M |
| 2018-12-31 | $-286.00K | $855.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | - |
| 2026-05-06 | - | - |
| 2026-02-25 | - | - |
| 2025-11-05 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-02-26 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- revmed.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades